By Stephen Nakrosis

Pfizer Inc. (PFE) said Friday the U.S. Food and Drug Administration approved lorbrena for certain lung cancer patients.

The approval was based on a multicenter Phase 1/2 study, B7461001, which evaluated lorbrena for the treatment of patients with certain types of lung cancer whose disease had progressed while receiving other treatments.

Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial, the company said.

Pfizer said the latest approval is the company's third for an oncology treatment, including two lung cancer medicines, within two months.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 02, 2018 17:22 ET (21:22 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Pfizer
Pfizer (NYSE:PFE)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Pfizer